MR. DAVID B BERMAN, LCSW-C
Social Work at Loch Raven Blvd, Baltimore, MD
License number
Maryland 721335
Category
Social Work
Type
Clinical
Address
Address
3900 Loch Raven Blvd BUILDING 2, Baltimore, MD 21218
Phone
(410) 605-7640
(410) 605-7691 (Fax)
(410) 605-7691 (Fax)
Organization information
See more information about DAVID B BERMAN at bizstanding.comDavid B Berman
3900 Loch Raven Blvd #2, Baltimore, MD 21218
Categories:
Social Workers
Phone:
(410) 605-7640 (Phone)
Professional information
Video Producer At Barmetrix
Position:
Media Producer at Barmetrix
Location:
Baltimore, Maryland Area
Industry:
Entertainment
Work:
Barmetrix
- Annapolis, MD since May 2011
-
Media Producer
Kitay Productions
Mar 2011 - Jul 2011
-
Intern
Towson Hillel
- Towson, MD Aug 2010 - May 2011
-
Marketing Chair
Education:
Towson University 2009 - 2011
B.S., Electronic Media and Film Anne Arundel Community College 2008 - 2008
Associates, Transfer Studies University of Maryland College Park 2007 - 2008
Anne Arundel Community College 2006 - 2006
Associate's degree, Transfer Studies
B.S., Electronic Media and Film Anne Arundel Community College 2008 - 2008
Associates, Transfer Studies University of Maryland College Park 2007 - 2008
Anne Arundel Community College 2006 - 2006
Associate's degree, Transfer Studies
Skills:
Final Cut Pro, After Effects, Video Production, Illustrator, InDesign, Dreamweaver, Video, Facebook, Social Media, Commercials, Film, Film Production, Television, Post Production, Screenwriting, Microsoft Excel, Prezi
Honor & Awards:
Towson Hillel's Board Member of the Month, September 2010
Vice President At A.r.g. Llc
Position:
Vice President at A.R.G. LLC
Location:
Baltimore, Maryland Area
Industry:
Environmental Services
Work:
A.R.G. LLC
since Jun 2008
-
Vice President
Tricat, Inc.
Oct 1995 - May 2008
-
Chief Commercial Officer
Akzo Nobel Chemicals
Apr 1988 - Sep 1995
-
Account Manager
Filtrol
1988 - 1990
-
Account Manager
Education:
Loyola College in Maryland 1978 - 1982
MBA, Marketing University of Maryland College Park 1974 - 1978
B.S., Chemistry
MBA, Marketing University of Maryland College Park 1974 - 1978
B.S., Chemistry
Skills:
Chemicals, Catalysis, Database Management, Refining, Catalyst, Database Admin, Process Simulation, Biofuels, Process Design
Urothelial Differentiation Of Urothelial Carcinoma: A Bladder Cancer Stem Cell Model
US Patent:
2009004, Feb 19, 2009
Filed:
Mar 24, 2008
Appl. No.:
12/079078
Inventors:
David M. Berman - Towson MD, US
William Matsui - Baltimore MD, US
Xiaobing He - Baltimore MD, US
William Matsui - Baltimore MD, US
Xiaobing He - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 51/08, A61P 35/00, A61K 39/395, A61B 5/055, A61K 49/00, A61K 51/10
US Classification:
424 149, 4241301, 424 93, 424 96, 424 111, 4241781, 4241831
Abstract:
The present invention provides a method of treating cancer in a patient (e.g., a human patient) in need thereof, the method comprising administering a therapeutically effective regimen, the regimen comprising administering to a patient in need thereof a compound that targets 67 laminin receptor (67LR). In a particular embodiment, the compound that targets 67LR is an antibody or antibody fragment. In particular, the present invention provides a method of treating cancer comprising administering to a patient in need thereof an antibody that binds to 67LR. The present invention also provides a method of treating cancer comprising administering to a patient in need thereof an antibody conjugate, wherein the antibody conjugate comprises an antibody that binds to 67LR linked to a therapeutic agent, a protein toxin, a cytotoxic agent or other moiety. The present invention provides pharmaceutical compositions for the treatment of cancer comprising an antibody that binds to 67LR in an amount effective to reduce cancer stem cells and/or cancer cells in a patient. The invention also provides for means to detect and monitor cancer stem cells based on their expression of 67LR.
David Monty Berman, Baltimore MD
Specialties:
Internal Medicine, Pathology, Anatomic Pathology, Anatomic Pathology & Clinical Pathology
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
Education:
The University of Texas Southwestern (1996)
Social Worker At V.a. Medical Center
Position:
Social Worker at V.A. Medical Center
Location:
Baltimore, Maryland Area
Industry:
Government Administration
Work:
V.A. Medical Center
-
Social Worker
David Monty Berman, Baltimore MD
Specialties:
Pathologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Anatomic Pathology (Pathology)
David B Berman, Baltimore MD
Specialties:
Social Work, Clinical Social Work
Address:
3900 Loch Raven Blvd STE 2, Baltimore 21218
(410) 605-7640 (Phone), (410) 605-7691 (Fax)
(410) 605-7640 (Phone), (410) 605-7691 (Fax)
Languages:
English
Hedgehog Signaling In Prostate Regeneration Neoplasia And Metastasis
US Patent:
2008009, Apr 24, 2008
Filed:
Oct 1, 2004
Appl. No.:
10/572430
Inventors:
Philip A. Beachy - Towson MD, US
David M. Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
David M. Berman - Towson MD, US
Sunil S. Karhadkar - Towson MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395, A61K 31/4355, A61K 31/7105, C12Q 1/48, C12Q 1/68, C12Q 1/02, A61K 38/16
US Classification:
4241301, 435 15, 435 29, 435 6, 435 71, 514 12, 514278, 514 44
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of determining the responsiveness of a prostate tumor to treatment with an Hh pathway antagonist.
Methods Of Predicting Behavior Of Cancers
US Patent:
2007023, Oct 4, 2007
Filed:
Nov 7, 2006
Appl. No.:
11/594281
Inventors:
Philip Beachy - Stanford CA, US
David Berman - Baltimore MD, US
Sunil Karhadkar - Towson MD, US
Edward Schaeffer - Baltimore MD, US
Angelo DeMarzo - Baltimore MD, US
David Berman - Baltimore MD, US
Sunil Karhadkar - Towson MD, US
Edward Schaeffer - Baltimore MD, US
Angelo DeMarzo - Baltimore MD, US
Assignee:
Johns Hopkins University - Baltimore MD
International Classification:
C12Q 1/02, G01N 33/53
US Classification:
435007100, 435029000
Abstract:
Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of identifying a prostate tumor of a subject as, or as capable of becoming lethal and/or metastatic.
Cancer Stem Cell Expression Patterns And Compounds To Target Cancer Stem Cells
US Patent:
2011002, Jan 27, 2011
Filed:
Apr 9, 2010
Appl. No.:
12/757649
Inventors:
David M. Berman - Towson MD, US
Xiaobing He - Ann Arbor MI, US
William Matsui - Baltimore MD, US
Xiaobing He - Ann Arbor MI, US
William Matsui - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 39/395, A61P 35/00, A61K 51/00, A61P 35/02
US Classification:
424 149, 4241301, 4241781, 4241381, 4241581
Abstract:
Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.